[
  {
    "ts": null,
    "headline": "Does Regeneron Offer Value After Recent Share Price Drop in 2025?",
    "summary": "Thinking about what to do with Regeneron Pharmaceuticals’ stock? You are not alone. The past year has been a wild ride, and it has left many investors reevaluating where the company stands. Regeneron’s share price has retreated by 51.2% over the last twelve months. For those who have been holding on even longer, the return over five years is a modest 1.3%. Even so, the stock is still in the spotlight thanks to its innovative biotech pipeline and recent market developments that continue to...",
    "url": "https://finnhub.io/api/news?id=382ad36a0a4f2432035c6bc56be89d23e73dc4db46d28587546aea85aab6f487",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757856535,
      "headline": "Does Regeneron Offer Value After Recent Share Price Drop in 2025?",
      "id": 136741741,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Thinking about what to do with Regeneron Pharmaceuticals’ stock? You are not alone. The past year has been a wild ride, and it has left many investors reevaluating where the company stands. Regeneron’s share price has retreated by 51.2% over the last twelve months. For those who have been holding on even longer, the return over five years is a modest 1.3%. Even so, the stock is still in the spotlight thanks to its innovative biotech pipeline and recent market developments that continue to...",
      "url": "https://finnhub.io/api/news?id=382ad36a0a4f2432035c6bc56be89d23e73dc4db46d28587546aea85aab6f487"
    }
  },
  {
    "ts": null,
    "headline": "BMO Capital Maintains a Buy on Regeneron Pharmaceuticals (REGN), Sets a $640 PT",
    "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best cheap stocks to buy for beginners. In a report released on September 8, Evan Seigerman from BMO Capital maintained a Buy rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), setting a price target of $640.00. The analyst cited various factors supporting the optimistic outlook, including the promising results […]",
    "url": "https://finnhub.io/api/news?id=4ff71ff01e4cf046dbbe1481548ab92578fb58fc69d688c74f0440d5150427b6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757830626,
      "headline": "BMO Capital Maintains a Buy on Regeneron Pharmaceuticals (REGN), Sets a $640 PT",
      "id": 136741742,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best cheap stocks to buy for beginners. In a report released on September 8, Evan Seigerman from BMO Capital maintained a Buy rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), setting a price target of $640.00. The analyst cited various factors supporting the optimistic outlook, including the promising results […]",
      "url": "https://finnhub.io/api/news?id=4ff71ff01e4cf046dbbe1481548ab92578fb58fc69d688c74f0440d5150427b6"
    }
  }
]